Paper Details

  1. Home
  2. Paper Details

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

Author: Andlin-SobockiP, BraunJ, BrophyS, CalinA, JönssonL, KobeltG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examines the cost-effectiveness of infliximab, a new treatment for ankylosing spondylitis (AS), considering the impact of this new medication on healthcare budgets. The study aims to assess the current financial burden of AS and evaluate the value of infliximab treatment.
Paper Details　
Original Abstract of the Article :
In the past, treatment options for ankylosing spondylitis (AS) have been limited, and the introduction of new treatments such as infliximab will have a noticeable impact on health-care budgets. The objective of this study was therefore to assess the current burden of the disease and estimate the cos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15226514

データ提供：米国国立医学図書館（NLM）

Ankylosing Spondylitis: Assessing Disease Burden and Treatment Cost-Effectiveness

The [ankylosing spondylitis (AS)] journey can be challenging, as it involves chronic inflammation that affects the spine and other parts of the body. This study investigates the [disease burden] of AS and the cost-effectiveness of treating it with [infliximab (Remicade)], a biologic medication that targets the inflammatory process.

The study highlights the significant impact of AS on patients' lives, both physically and financially. However, the introduction of new treatments like infliximab has the potential to significantly improve outcomes. The research focuses on evaluating the cost-effectiveness of infliximab, considering both its effectiveness in managing symptoms and its impact on healthcare costs. It's like exploring a desert oasis, where the benefits of a new water source must be weighed against its cost and accessibility.

Infliximab: A Cost-Effective Treatment for Ankylosing Spondylitis?

The study's findings suggest that infliximab can be a cost-effective treatment option for AS, considering its potential to improve patients' quality of life and reduce healthcare costs associated with managing the disease. It's like investing in a long-term water conservation project, where the initial costs are balanced by the long-term benefits of a sustainable water supply.

Managing Ankylosing Spondylitis: Balancing Cost and Effectiveness

The study underscores the importance of carefully considering the cost-effectiveness of treatments for AS, particularly in light of the availability of new therapies. It's like managing a desert oasis, ensuring that the resources allocated for its maintenance are balanced with its potential to support life and well-being.

Dr.Camel's Conclusion

This study provides valuable insights into the burden of ankylosing spondylitis and the potential of infliximab to improve patient outcomes. It highlights the critical need for a balanced approach to healthcare resource allocation, ensuring that effective treatments are accessible and affordable for those in need.

Date :
  1. Date Completed 2004-11-01
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

15226514

DOI: Digital Object Identifier

keh271

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.